Results 31 to 40 of about 66,840 (318)
Pharmacology Research & Perspectives, 2022 Advanced hepatocellular carcinoma (HCC) results in generally poor clinical outcomes and necessitates better therapeutic strategies. Ivermectin, which is an existing anti‐parasitic drug, has been recently identified as a novel anti‐cancer drug.
Haofeng Lu +7 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Pancreatic cancer is an aggressive cancer characterized by high mortality and poor prognosis, with a survival rate of less than 5 years in advanced stages. Ivermectin, an antiparasitic drug, exerts antitumor effects in various cancer types.
D. Lee +10 more
semanticscholar +1 more source
Pathogens, 2020 A clinical trial performed in the Democratic Republic of Congo (DRC), among persons with epilepsy (PWE) infected with Onchocerca volvulus treated with anti-seizure medication suggested that ivermectin reduces the seizure frequency. We assessed the effect
Alfred Dusabimana +9 more
doaj +1 more source
Asian Pacific Journal of Tropical Medicine, 2021 Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A randomized, double-blind, placebo-controlled, multicenter clinical trial
Morteza Shakhsi Niaee +14 more
doaj +1 more source
Human myiasis in Ecuador. [PDF]
, 2020 We review epidemiological and clinical data on human myiasis from Ecuador, based on data from the Ministry of Public Health (MPH) and a review of the available literature for clinical cases.
Calvopina, M +5 more
core +1 more source
BMC Infectious Diseases, 2021 Background and objectives An effective treatment option is not yet available for SARS-CoV2, which causes the COVID-19 pandemic and whose effects are felt more and more every day.
N. Okumus +14 more
semanticscholar +1 more source
Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. [PDF]
, 2005 In order to identify the factors influencing compliance with mass ivermectin treatment for onchocerciasis control, a cross-sectional study was carried out in Bushenyi District, Uganda. Data were collected by interviewing 839 individuals who were randomly
Ndyomugyenyi, Richard +2 more
core +1 more source
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19
medRxiv, 2020 Caly et al.1 reported that ivermectin inhibited severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) in vitro for up to 48 hours using ivermectin at 5 μM.
V. Schmith, Jie Zhou, L. Lohmer
semanticscholar +1 more source
Journal of Medical Virology, 2021 Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID‐19 ...
S. Abd-Elsalam +15 more
semanticscholar +1 more source
medRxiv, 2021 Introduction: In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV- 2 viral replication, but questions remained as to In-vivo applications.
O. Babalola +9 more
semanticscholar +1 more source